Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Ulcerative Colitis: Recent Advances in Clinical Management
jcm-logo
Submit to JCM Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Ulcerative Colitis: Recent Advances in Clinical Management

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Gastroenterology & Hepatopancreatobiliary Medicine".

Deadline for manuscript submissions: closed (31 March 2025) | Viewed by 3007

Special Issue Editors

Dr. Filippo Vernia

E-Mail
Guest Editor
Department of Life, Health, and Environmental Sciences, Division of Gastroenterology, Hepatology, and Nutrition, University of L’Aquila, Piazza S. Tommasi, 1- Coppito, 67100 L’Aquila, Italy
Interests: inflammatory bowel disease; Crohn’s disease; ulcerative colitis; advanced therapies; nutrition; surrogate markers of activity
Dr. Angelo Viscido

E-Mail Website
Guest Editor
Department of Life, Health, and Environmental Sciences, Division of Gastroenterology, Hepatology, and Nutrition, University of L’Aquila, Piazza S. Tommasi, 1- Coppito, 67100 L’Aquila, Italy
Interests: inflammatory bowel disease; Crohn’s disease; ulcerative colitis; advanced therapies; nutrition; surrogate markers of activity
Dr. Latella Giovanni

E-Mail Website
Guest Editor
Department of Life, Health, and Environmental Sciences, Division of Gastroenterology, Hepatology, and Nutrition, University of L’Aquila, Piazza S. Tommasi, 1- Coppito, 67100 L’Aquila, Italy
Interests: inflammatory bowel disease; Crohn’s disease; ulcerative colitis; advanced therapies; nutrition; surrogate markers of activity
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleague,

Therapeutic strategies for inflammatory bowel diseases are rapidly evolving due to the development of a large number of different molecules aimed at specific points of the inflammatory cascade. In many, but not all, instances, therapy is also effective in extraintestinal manifestation, which often impairs the quality of life of ulcerative colitis patients.

The clinical scenario is rapidly changing, and new information is expanding at an ever-quickening pace. In parallel, increasing attention has been focused on the role of the diet and nutrition to prevent the development of IBD and improve clinical outcomes. Thus, the choice of the best treatment of individual patients represents a significant challenge for healthcare professionals.

This Special Issue is aimed at extensively exploring the latest advancements in the treatment of ulcerative colitis, critically examining current and emerging therapies as well as dietary and nutritional interventions. It is open for submissions of manuscripts reporting original research, as well as comprehensive reviews of the current state of the art. We hope that it will represent an effective tool for disseminating the latest research on and critical evaluations of therapeutic strategies in ulcerative colitis. Timing is thus central, and we hope to bring the Special Issue online in six months.

We therefore encourage the submission of papers that are within the scope of this Special Issue, requesting that authors send a short abstract or tentative title in advance, to avoid possible overlapping or duplication. The final manuscript is expected in ten to twelve weeks.

Based on your expertise in the field, we think that you could make an excellent contribution. Thank you in advance for your attention.

Dr. Filippo Vernia
Dr. Angelo Viscido
Dr. Latella Giovanni
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • ulcerative colitis
  • advanced therapies
  • nutrition
  • extraintestinal manifestations
  • surrogate markers of activity

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

15 pages, 1563 KiB  
Review
Joint Manifestations in Inflammatory Bowel Diseases, “Red Flags” for the Early Recognition and Management of Related Arthropathies: A Narrative Review
by Ilenia Di Cola, Luca Vallocchia, Paola Cipriani and Piero Ruscitti
J. Clin. Med. 2025, 14(5), 1558; https://doi.org/10.3390/jcm14051558 - 26 Feb 2025
Viewed by 693
Abstract
Inflammatory bowel diseases (IBDs), including Crohn’s disease and ulcerative colitis, frequently present with extra-intestinal manifestations. Virtually all patients with IBD could be at risk for developing inflammatory arthropathies within the spectrum of spondyloarthritis (SpA). In this context, prompt recognition of musculoskeletal “red flags” [...] Read more.
Inflammatory bowel diseases (IBDs), including Crohn’s disease and ulcerative colitis, frequently present with extra-intestinal manifestations. Virtually all patients with IBD could be at risk for developing inflammatory arthropathies within the spectrum of spondyloarthritis (SpA). In this context, prompt recognition of musculoskeletal “red flags” (lower back pain, dactylitis, enthesitis, swelling of peripheral joints, musculoskeletal chest pain, family history of SpA, psoriasis, and anterior uveitis) is crucial for early referral and multidisciplinary management by gastroenterologists and rheumatologists. Recent advances have refined diagnostic tools including questionnaires, alongside imaging modalities and laboratory markers, enhancing the detection of SpA in IBD patients. Effective treatment strategies targeting both gastrointestinal and musculoskeletal symptoms may significantly reduce long-term morbidity in these patients. In this narrative review, we aimed to underscore the importance of integrating clinical, diagnostic, and therapeutic approaches for optimal patient management and outcome over time. Full article
(This article belongs to the Special Issue Ulcerative Colitis: Recent Advances in Clinical Management)
►▼ Show Figures

Figure 1

19 pages, 346 KiB  
Review
Efficacy and Safety of Janus Kinase-Inhibitors in Ulcerative Colitis
by Benedetto Neri, Roberto Mancone, Mariasofia Fiorillo, Sara Concetta Schiavone, Stefano Migliozzi and Livia Biancone
J. Clin. Med. 2024, 13(23), 7186; https://doi.org/10.3390/jcm13237186 - 27 Nov 2024
Cited by 3 | Viewed by 1872
Abstract
Background: Janus kinase-inhibitors (JAK-i) have recently been approved for treating patients with Ulcerative Colitis (UC); therefore, further information is needed, particularly regarding efficacy and safety. Objectives: To provide a comprehensive review regarding the efficacy and safety of currently available JAK-i in [...] Read more.
Background: Janus kinase-inhibitors (JAK-i) have recently been approved for treating patients with Ulcerative Colitis (UC); therefore, further information is needed, particularly regarding efficacy and safety. Objectives: To provide a comprehensive review regarding the efficacy and safety of currently available JAK-i in UC. Methods: The PubMed and Scopus databases were considered, searching for ‘JAK’, ‘JAK-inhibitor’, ‘Janus Kinases’, ‘Tofacitinib’, ‘Filgotinib’, ‘Upadacitinib’, individually or in combination with ‘IBD’, ‘Ulcerative Colitis’, ‘safety’, ‘efficacy’, ‘study’ and ‘trial’. The search was focused on full-text papers published in English, with no publication date restrictions. Results: The efficacy and safety of JAK-i approved for treating patients with UC have been summarized. These included Tofacitinib, Filgotinib and Upadacitinib. Findings from both clinical trials and real-life studies in UC were reported, with particular regard to their efficacy in inducing clinical response and remission, steroid-free remission and endoscopic and histological healing. Overall, JAK-i proved to be effective and safe in selected subgroups of patients with UC. The rapid onset of action and the oral route of administration represent the most relevant characteristics of these drugs. Safety concerns using Tofacitinib in subgroups of patients (infections, hypercholesterolemia, venous thromboembolism and cardiovascular events) were initially raised. More recently, all JAK-i for UC showed an overall satisfactory safety profile. However, indication should be carefully given. Conclusions: The use of JAK-i UC is promising, although no predictive markers of response are currently available. Optimizing their use, as monotherapy or combined with other immunomodulators, may increase their efficacy in appropriately selected subgroups of patients with UC. Full article
(This article belongs to the Special Issue Ulcerative Colitis: Recent Advances in Clinical Management)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop